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Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma including two major subtypes, alveolar
rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS). Increasing evidence suggests that oncogenesis of RMS
involves multistages of signalling protein dysregulation which may include prolonged activation of serine/threonine kinases such as
phosphoinositide-dependant kinase-1 (PDK-1) and AKT. To date, whether PDK-1/AKT pathway is activated in RMS is unknown. This
study was to examine phosphorylation status of AKT and to evaluate a novel small molecular inhibitor, OSU-03012 targeting PDK-1
in RMS. We examined phosphorylation levels of AKT using ARMS and ERMS tissue microarray and immunohistochemistry staining.
Our results showed phospho-AKT
Thr308 level is elevated 42 and 35% in ARMS and ERMS, respectively. Phospho-AKT
Ser473 level is
also increased 43% in ARMS and 55% in ERMS. Furthermore, we showed that OSU-03012 inhibits cell viability and induces apoptosis
in ARMS and ERMS cell lines (RH30, SMS-CTR), which express elevated phospho-AKT levels. Normal cells are much less sensitive to
OSU-03012 and in which no detectable apoptosis was observed. This study showed, for the first time, that PDK-1/AKT pathway is
activated in RMS and may play an important role in survival of RMS. PDK-1/AKT pathway may be an attractive therapeutic target for
cancer intervention in RMS using OSU-03012.
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Rhabdomyosarcoma (RMS) is the most common soft-tissue
sarcoma of childhood. Approximately 350 new cases occur each
year in the United States and they account for 4% of all childhood
malignancies (Ries et al, 1999). Most of these tumours arise in the
head and neck region, genitourinary tract and extremity. On the
basis of histological criteria, it can be classified into two major
subtypes, alveolar rhabdomyosarcoma (ARMS) and embryonal
rhabdomyosarcoma (ERMS). Emerging evidence has been shown
that the malignant growth of RMS involves a multistep process of
signalling protein dysregulation that includes prolonged activation
of serine/threonine kinases which may include 3-phosphoinosi-
tide-dependant kinase-1 (PDK-1)/AKT pathway. PDK-1 is a serine/
threonine kinase that is activated in response to insulin and
growth factor treatment by a mechanism involving phosphoinosi-
tide-3 kinase (PI3-K) (Mora et al, 2004). PDK-1 was identified by
its ability to phosphorylate and activate AKT (Alessi et al, 1997;
Stokoe et al, 1997), p70 S6 kinase (Alessi et al, 1998), and possibly
protein kinase C (PKC) isozymes (Le Good et al, 1998; Balendran
et al, 2000). PDK-1 can transform normal human cells and may be
involved in invasion and metastasis process (Zeng et al, 2002; Xie
et al, 2003, 2006). PDK-1 and its downstream target AKT are
frequently phosphorylated and activated in multiple types of
cancers (Cheng et al, 1992; Sun et al, 2001; Lin et al, 2005).
Constitutive activation of PI3-K/PDK-1/AKT signalling mediates
the survival signals and confers resistance to apoptosis induced by
anticancer cytotoxic agents in human cancer cells (Page et al, 2000;
Nesterov et al, 2001; Clark et al, 2002). Further, inhibition of PDK-
1 using antisense oligonucleotides decreased cell proliferation and
increased apoptosis in cancer cells which expresses constitutively
active PDK-1/AKT pathway (Flynn et al, 2000). The effect of PDK-1
inhibition on cell proliferation and survival by antisense
oligonucleotides implicates PDK-1 as a potential therapeutic target
for human cancers including RMS. To date, the activation of PDK-
1/AKT pathway in RMS has not been reported. Our results
reported here demonstrates AKT was frequently phosphorylated
and activated in ARMS and ERMS tissue microarray (TMA)
indicating PDK-1/AKT pathway is activated in human RMS. Since
there has been no significant improvement in the outcome for the
treatment of RMS in the past 20 years, novel therapeutic methods
are urgently needed. Given that PDK-1/AKT pathway is constitu-
tively activated in RMS and may contribute to progression of the
disease and possibly the anticancer drug resistance, there is a
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scritical need to develop inhibitors of PDK-1/AKT pathway as
potential treatment for RMS. We have recently developed a novel
small molecule compound, OSU-03012, which targets PDK-1
pathway (Zhu et al, 2004). Therefore, we explored the potency of
this compound for treatment of RMS. The compound was tested in
RMS cell lines that express high levels of phospho-AKT, namely
RH30 and SMS-CTR. Our results demonstrated OSU-03012
inhibited AKT phosphorylation. In addition, OSU-03012 led to
cell viability decline and induced apoptosis in RMS cells (RH30
and SMS-CTR) but had minimal effect in normal human cells.
These data showed the activation of PDK-1/AKT pathway in RMS
and this pathway may play an important role in survival of RMS.
These results suggest that PDK-1, which is an upstream regulator
of AKT, may be an attractive therapeutic target for cancer
intervention in RMS and OSU-03012 might be a potential
therapeutic treatment for RMS patients, especially those cases
with PDK-1/AKT pathway activated.
MATERIALS AND METHODS
Cell lines and cell culture
Human ARMS cell lines, RH3, RH30, CW9019 and ERMS cell lines,
RD2 and SMS-CTR were maintained in DMEM supplemented with
10% fetal bovine serum (FBS; Fisher Scientific, Chicago, IL, USA).
Tissue microarray slides and immunohistochemistry
Human RMS TMA slides were obtained from the Children’s
Oncology Group (COG). The ERMS TMA block contains 32 unique
ERMS cases with two types of control tissues; one control tissue is
normal skeletal muscle (five cases) and the other is ARMS (five
cases). Each case averaged three tissue cores (range 1–9 cores),
which were each 1.0mm in diameter and randomly distributed
throughout the block. The ARMS TMA also contains 32 unique
cases with identical block design as defined above. In addition to
five normal skeletal muscle control cases, five ERMS cases were
included as controls. Rhabdomyosarcoma diagnoses were made
via review by COG and STSC (Soft Tissue Sarcoma Committee)
designated reviewers using the International Classification of
Rhabdomyosarcomas (Qualman et al, 1998).
These slides were baked at 601C for 1h, deparaffinised in xylene
three times, transferred through two changes of 100% ethanol, and
then dehydrated with graded ethanol. Antigen retrieval was carried
out by boiling the slides in a beaker filled with 10mM sodium
citrate (pH 6.0) or 1mM EDTA (pH 8.0). Endogenous peroxidase
activity was quenched by 10-min incubation in 3% hydrogen
peroxide. After antigen retrieval, the slides were briefly rinsed with
0.1% Tween/1 TBS (0.1% TBST) two times and then washed
three times for 10min each at room temperature to remove
nonspecific background binding. The protein blocking were
performed by incubating the specimens in 5% normal goat serum
or normal horse serum in 0.1% TBST for 1h. Primary antibody
was applied at 41C overnight (1:50 dilution of rabbit monoclonal
anti-human phospho-specific antibodies from Cell Signaling
Technology, Beverly, MA, USA and Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) in 0.1% TBST with normal serum. The
phospho-specific antibodies we tested are phospho-AKT (Thr308),
phospho-AKT (Ser473) (Cell Signaling Technology). After a series
of TBS rinses as described above, bound antibody was subse-
quently detected using a VECTASTAIN ABC KIT from Vector
Laboratories Inc. (Burlingame, CA, USA). The sections were then
visualised with a 5–30min incubation of 3-amino-9-ethylcarbazole
(AEC) high-sensitivity substrate chromogen from DakoCytoma-
tion (Carpinteria, CA, USA). Finally, the slides were counterstained
with haematoxylin and mounted with CRYSTAL/MOUNTt
(Biomeda Corp., Foster City, CA, USA) for long-term preservation.
Evaluation of immunohistochemical staining
Immunohistochemical staining was scored under the microscope
by eye. The staining intensity was graded relatively based on the
following scale: 0, no staining; 1, weak staining; 2, moderate
staining and 3, intense staining (Dolled-Filhart et al, 2003). For
specimens that were uninterpretable or were missing in most of
the cancer tissues, a score of not applicable (NA) was given.
Scoring of the TMA was completed by at least two independent
observers (LC and FH). Discrepant scores between the two
observers were rescored to arrive at a single final score. In order
for a tumour specimen to be considered positive, it had to have a
score of 2 or greater from both observers.
Cell viability assay
Cell viability was analysed by the [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] (MTT) assay in three repli-
cates. Cells were grown in 10% FBS-supplemented DMEM in
96-well flat-bottomed plates overnight and were exposed to various
concentrations of small molecule inhibitors dissolved in dimethyl-
sulphoxide in the same medium. At the time of assay end point,
MTT was added to the cultures and incubated for 3–4h.
Solubilisation buffer was then added. Plates were kept overnight
in the dark to allow dissolving the formazan. Absorbance at
595nm was determined on a plate reader. IC50, the drug
concentration at which 50% growth inhibition is achieved, was
calculated with WinNonlin Software (Scientific Consulting Inc.,
Apex, NC, USA).
Western blot analysis
Total protein lysates (50–100mg per lane), as determined by BCA
protein assay kit, were separated by 10% SDS–polyacrylamide gels
and transferred onto PVDF membrane. Membranes were blotted
with a 1:1000 dilution of antibodies against phospho-AKT (Ser473
or Thr308), total AKT, cleaved poly(ADP-ribose) polymerase
(PARP) (Cell Signaling Technology), or phospho-p70 S6 kinase
(Thr229) (R&D Systems Inc., Minneapolis, MN, USA). The same
membranes were analysed with a 1:1000 dilution of anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal
antibody (Chemicon International Inc., Temecula, CA, USA) as a
protein loading control. All blots were incubated with 1:600
dilution of secondary fluorescein-linked anti-mouse or anti-rabbit
antibody followed by incubation with 1:2500 dilution of alkaline
phosphatase-conjugated anti-fluorescein antibody (Amersham
Biosciences, Piscataway, NJ, USA). Blots were scanned with
ImageQuant software using an ECF Western blotting detection
system (Amersham Biosciences) on a Molecular Dynamics Storm
PhosphorImager (Sunnyvale, CA, USA).
Immunofluorescent staining
Cells were seeded on sterile coverslips in a six-well plate overnight.
Cells were treated with 10mM OSU-03012 for 24h and then were
fixed with ice-cold methanol. Three washes followed fixation using
1 PBS. During the third wash, coverslips were transferred onto a
new six-well plate. Cells were blocked in 1 PBS with 10% normal
horse serum for 1h and incubated with primary rabbit antibody
that recognises cleaved-caspase-3 (Asp175) (Cell Signaling Tech-
nology) with 1:100 dilution overnight. Excess antibody was
removed followed by three washes using 1 PBS with constant
agitation. Secondary goat anti-rabbit lgG (HþL) Alexa Fluo
R 594
antibody (Invitrogen, Carlsbad, CA, USA) with 1:1000 dilutions
was incubated with 1% bovine serum albumin in 1 PBS for 1h.
After three washes using 1 PBS, nuclei were stained using 40,
6-diamidino-2-phenylindole dihydrochloride (100ngml
 1) for
5min, and rinsed three times using 1 PBS. The fluorescence
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smicroscopic photographs were documented using LEICADM-IRB
inverted fluorescent microscope (Leica Microsystems Inc., Ban-
nockburn, IL, USA) with an attached Diagnostic RT-SE6 mono-
chrome digital camera (Diagnostic Instruments Inc., Sterling
Heights, MI, USA).
RESULTS
Increased frequency of phospho-AKT levels in RMS tissues
and cells
To determine whether PDK-1/AKT pathway is activated in human
RMS, immunohistochemistry was used to detect the expression
levels of phospho-AKT in ARMS and ERMS. Clinicopathological
features of RMS patients are given in Table 1. The age of the
patients in these cases are between 0 and 19 with mean 9.1 in
ARMS and 5.8 in ERMS, and most of the cases are in stage III
(Table 1). In each type of ARMS and ERMS, there are 32 cases
along with 5 normal tissues as negative controls. Our results
showed that phospho-AKT (Thr308) was moderate-to-strong
expression in 42% of ARMS and 35% of ERMS cases (Figure 1A;
Table 2). Phospho-AKT (Ser473) was moderate-to-strong expres-
sion in 43% of ARMS and 55% of ERMS cases (Figure 1A, Table 2).
In contrast, normal tissues are mostly negative to weak staining.
We also examined the relationship of phospho-AKT with
clinicopathological parameters, such as tumour subtype, stage
and age. But no significant correlation was found (data not
shown). Since Thr308 of AKT is phosphorylated by PDK-1 (Alessi
et al, 1997), these results suggest that PDK-1 is also activated in
RMS. We also examined a couple of RMS cell lines for AKT
phosphorylation. The cell lines include human skeletal muscle
myoblasts (HSMM), ARMS cell line RH30, CW9019, RH3 and
ERMS cell line RD2, SMS-CTR. The RH30 and SMS-CTR cells
expressed the highest level of phospho-AKT (Thr308 and Ser473)
respectively among alveolar and embryonal cell lines (Figure 1B).
Therefore, they were further used to examine the inhibitory effects
of OSU-03012 on RMS cells.
Novel small molecule compound, OSU-03012 targeting
PDK-1 inhibits AKT phosphorylation in RMS cells
To study the inhibitory effects of small molecule inhibitor OSU-
03012, that targets PDK-1, RMS cell line RH30 and SMS-CTR,
which express elevated AKT phosphorylation levels at Thr308 (a
PDK-1 phosphorylation site), were treated with 10mM OSU-03012
for 8h, respectively. Our data showed that OSU-03012 treatment
resulted in inhibition of AKT phosphorylation in both RH30
(Figure 2A) and SMS-CTR cell lines (Figure 2B) but did not inhibit
Table 1 Clinicopathological parameters of ARMS and ERMS patients
used
Number of patients
Variable ARMS (n¼32) ERMS (n¼32)
Gender
Male 13 24
Female 19 8
Age (years)
0–4 11 18
5–14 14 10
15–19 7 4
Mean 9.1 5.8
Median 10 4
Stage
I5 7
II 5 4
III 15 14
IV 7 7
Primary site
Head and neck 9 10
Extremity 13 3
Genitourinary 7 10
Others 3 9
Normal Normal ERMS ARMS
p-AKT (Thr308)
p-AKT (Thr308)
p-AKT (Ser473)
A
B
p-AKT (Ser473)
HSMM RH30 CW9019 RD2 SMS-CTR RH3
Total AKT
GAPDH
Figure 1 Expression of phosphorylated AKT in rhabdomyosarcoma (RMS) patient tissues and cell lines. (A) Immunohistochemical (IHC) staining of RMS
tissue microarrays (TMAs) that contain both normal and cancer tissues using phospho-AKT (Thr308) and phospho-AKT (Ser473) antibodies. (B) The levels
of phosphorylated AKT were examined using antibodies to threonine 308 and serine 473 in a series of RMS cell lines.
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sERK phosphorylation, which is independent of AKT pathway (data
not shown). Phosphorylation of p70S6K at threonine 229, one of
the downstream targets of PDK-1, was also inhibited by OSU-
03012 in RH30 cells (Figure 2A), but much less inhibited in SMS-
CTR cells (data not shown). To further study the kinetics of the
inhibition caused by OSU-03012, RH30 and SMS-CTR cells were
treated with 10mM OSU-03012 for different time course. Western
blotting analysis showed that inhibition of p-AKT (Thr308) was
observed as early as 2-h treatment in SMS-CTR cells (Figure 2D),
whereas that was only seen at 6-h and 8-h treatment in RH30 cells
(Figure 2C). In SMS-CTR, level of p-AKT (Ser473) slightly
decreased after 2-h treatment and further inhibition was observed
after 4-h treatment (Figure 2D). In addition, OSU-03012 inhibited
p-AKT (Ser473) starting after 6-h treatment in RH30 cells
(Figure 2C).
OSU-03012 inhibits cell viability in RMS cells
Next, we examined the inhibitory effect of OSU-03012 on cell
viability in RMS cells. RH30 and SMS-CTR cells were treated with
OSU-03012 at 2.5, 5, 7.5 and 10mM respectively for up to 3 days. On
each day, cell viability was determined (Figure 3). OSU-03012
reduced cell viability and induced cell death in both RH30 and
SMS-CTR cells in a time and dose-dependent manner (Figure 3A
and B). There was more than 70% decrease in cell viability of both
RH30 and SMS-CTR with 10mM OSU-03012 compound treatment
for 24h. The IC50 value for RH30 is 6.3±1.1mM and for SMS-CTR
is 5.0±1.6mM. In comparison, human fibroblast (HFF) was much
less sensitive to OSU-03012 in cell viability. There was still nearly
60% cell survival upon 10mM OSU-03012 treatment for 3 days
(Figure 3C).
Phosphoinositide-3 kinase is a major upstream activator of
PDK-1. We also compared the potency on reducing cell viability of
inhibiting PI3-K using an existing and potent PI3-K inhibitor,
LY294002 with inhibiting PDK-1 using OSU-03012 in RH30 and
SMS-CTR cells. To compare the effect of LY294002 on cell viability
to that of OSU-03012, RH30 and SMS-CTR cells were treated with
LY294002 at 5, 10, 20 and 40mM concentration for up to 3 days.
Since PI3-K is an upstream activator of PDK-1, we predicted that
inhibition at PI3-K level may be more potent than inhibition at
PDK-1 level. However, to our surprise, LY294002 showed much
less inhibitory effect on cell viability compared to the same doses
used with OSU-03012 (Figure 3D and E). Our results suggested that
the IC50 of OSU-03012 was four times lower in RH30 cells and nine
times lower in SMS-CTR cells than LY294002 (data not shown).
These results indicate that novel OSU-03012 compound may be a
more potent inhibitor to PDK-1/AKT pathway than the existing
PI3-K inhibitor, LY294002 to treat RMS.
OSU-03012 induces apoptosis in RMS cells
To explore whether OSU-03012 induces apoptosis in RMS cells, we
examined levels of cleaved-caspase-3 (a biomarker for apoptosis)
by immunofluorescence. OSU-03012 treatment resulted in in-
creased cleaved-caspase-3 in both RH30 and SMS-CTR cells
(Figure 4A). However, OSU-03012 did not induce any detectable
apoptosis in normal HFFs and normal HSMMs, which are negative
controls for RMS cells (Figure 4B). Western blotting showed that
OSU-03012 treatment led to cleavage of PARP in both RH30 and
SMS-CTR cell lines (Figure 2A and B), which is an other evidence
of apoptosis. These suggest that OSU-03012 treatment results in
apoptosis in both RMS cell lines RH30 and SMS-CTR.
DISCUSSION
AKT plays a critical role in controlling the balance between cell
survival and apoptosis. The activation of AKT signalling pathway
has been reported in several types of cancers. In this study, we
Table 2 Elevated phosphorylation levels of AKT in ARMS and EMRS
patients
a
Positive (%)
ARMS (n¼32) ERMS (n¼32)
p-AKT (T308) 42 35
p-AKT (S473) 43 55
aThe immunostaining intensity was scored under the microscope on the following
scale: 0, no staining; 1, weak staining; 2, moderate staining and 3, intense staining.
Scoring of the tissue microarray was completed by at least two independent
researchers. Scores of normal tissues are 0 or 1. Scores of 2 and 3 of IHC staining in
ARMS and ERMS tissues were considered as positive. % positive: percentage of
numbers of positive divided by the total number of specimens.
p-AKT (Ser473)
GAPDH
p-P70S6K (Thr229)
p-AKT (Thr308)
Untreated DMSO 10 M OSU
Untreated DMSO 10 M OSU
A
Cleaved PARP Cleaved PARP
p-AKT (Ser473)
GAPDH
p-AKT (Thr308)
B
GAPDH
p-AKT (Ser473)
p-AKT (Thr308)
p-AKT (Ser473)
p-AKT (Thr308)
04 68 Time (h) Time (h) C
GAPDH
02468 D
Figure 2 Effects of phosphoinositide-dependant kinase-1 (PDK-1) inhibitor OSU-03012 (OSU) on rhabdomyosarcoma (RMS) cell lines. (A) RH30 cells
were treated for 8h with 10mM OSU-03012. OSU-03012 downregulates AKT phosphorylation at both threonine 308 and serine 473. Phosphorylation of
p70S6K at threonine 229, one of the downstream targets of PDK-1, was also inhibited by OSU-03012. Poly(ADP-ribose) polymerase (PARP) cleavage was
measured with anti-cleaved-PARP antibody by western blotting. (B) SMS-CTR cells were treated as above. OSU-03012 inhibits AKT phosphorylation at
both threonine 308 and serine 473. Poly(ADP-ribose) polymerase (PARP) cleavage was measured with anti-cleaved-PARP antibody by western blotting. (C)
RH30 cells were treated with 10mM OSU-03012 for 4, 6 and 8h respectively. AKT phosphorylation was inhibited in a time-dependent manner. (D) SMS-
CTR cells were treated with 10mM OSU-03012 for 2, 4, 6 and 8h respectively. Time course inhibition of phosphorylated-AKT was shown by western blot.
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sexplored if the status of AKT level influences cell survival in RMS.
Here, we report that AKT phosphorylation is elevated in both RMS
tissue samples and cell lines. Interference of AKT signalling
pathway with OSU-03012, a small molecule compound targeting
PDK-1 activity (Zhu et al, 2004), inhibited cell growth and induced
apoptosis in RMS cell lines, RH30 and SMS-CTR.
Elevation of AKT phosphorylation at both phospho-sites Ser473
and Thr308 is found in both ARMS and ERMS tissues as well as cell
lines. Among 32 ARMS tissue samples, 43% are positive in p-
AKT
ser473 antibody immunostaining; whereas 42% are positive in
p-AKT
Thr308 antibody immunostaining. Among 32 ERMS tissue
samples, 55 and 35% are positive in p-AKT
ser473 and p-AKT
Thr308
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Figure 3 Effects of OSU-03012 and LY294002 on cell viability (A–E). RH30 (A), SMS-CTR (B) and human fibroblast (HFF) (C) cells were exposed to
OSU-03012 at the designated concentrations and cell viability was evaluated on days 1, 2 and 3, respectively. There was a dose-dependent decrease in cell
viability upon treatment with increasing concentration of the inhibitor. Human fibroblast is much less sensitive to OSU-03012 compared to
rhabdomyosarcoma cell lines. RH30 and SMS-CTR cells were treated with Ly294002 at the indicated concentrations and cell viability was evaluated on days
1, 2 and 3 respectively (D and E).
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santibody immunostaining respectively. We analysed the associa-
tion between positive immunostaining (score¼2 or 3) with the
stage or the subtype of the tumour, but no statistically significant
correlation was found. This might be due to the limited patient
sample number in our study. However, there is an apparent
association between p-AKT
ser473 and p-AKT
Thr308 antibody posi-
tive immunostaining (Po0.05) in both subtypes of RMS. Elevated
p-AKT levels are also found in RMS cells. Phosphorylation at both
threonine 308 and serine 473 are required for the activation of
AKT. Elevation of AKT phosphorylation may be due to any
activation of upstream protein kinase receptor Her2 or EGFR
which activates AKT via PDK-1 in RMS (Zhou et al, 2004). In
addition, reduction in activity of the negative regulator of AKT
signalling, such as PTEN, might also contribute to the elevation of
p-AKT. However, PTEN protein levels of most RMS cell lines we
tested are similar as normal cells except that of RH30 and RH3 are
at very low level similar to a PTEN-defective MDA-MB-468 breast
cancer cell line (data not shown) (deGraffenried et al, 2004).
Further studies are necessary to elucidate the underlying mechan-
isms leading to activation of AKT signalling in RMS.
Our data suggest that RMS cell lines that express high level of
phospho-AKT, at least RH30 and SMS-CTR, seem to depend on
AKT pathway for cell proliferation and survival. As shown here,
intervention of AKT signalling pathway using a small molecule
compound OSU-03012 targeting PDK-1, an upstream regulator of
AKT, inhibited cell survival. OSU-03012 was potent in inhibiting
cell growth in both RH30 and SMS-CTR with the concentration
resulting in 50% growth inhibition values of 6.3 and 5.0mM,
respectively. OSU-03012 was also able to effectively induce
apoptosis in both RH30 and SMS-CTR through caspase-3 and
PARP cleavages. Further, we observed that OSU-03012 treatment
was able to repress phospho-AKT levels in both RH30 and SMS-
CTR cells. In this case, PDK-1/AKT pathway may serve as a
potential therapeutic target in RMS cells. Interestingly, OSU-03012
also slightly inhibited the phosphorylation of AKT at both Ser473
and Thr308 sites (data not shown). Since cell viability assay in our
study showed that OSU-03012 treatment has little effect on HFF
cells, it suggests that PDK-1/AKT pathway may not be essential for
the survival of normal cells, such as HFF. In contrast, PDK-1/AKT
pathway is indispensable for the survival of cancer cell lines, such
as RH30 and SMS-CTR.
Importantly, compared to the effects of LY294002, a potent PI3-
K/AKT signalling pathway inhibitor (Altomare et al, 2004), IC50 of
OSU-03012 is several folds lower in RMS cells. These results
indicate that novel OSU-03012 compound may be a more potent
inhibitor to PDK-1/AKT pathway than the currently potent
inhibitor of PI3-K/AKT, LY294002 to treat childhood RMSs.
Further, although OSU-03012 is effective in inducing apoptosis
in RH30 and SMS-CTR cells (Figure 4A), it did not induce
detectable apoptosis in normal human cells such as HSMM and
HFF (Figure 4B). Therefore, an orally active compound, OSU-
03012 may have a future clinical application for the treatment of
both ARMS and ERMS that express activated PDK-1/AKT
signalling pathway.
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Figure 4 Effects of PDK-1 inhibitor OSU-03012 on apoptosis induction. (A and B) The cells were treated with 10mM OSU-03012 for 24h and fixed.
Caspase-3 cleavage (shown in red) was evaluated by immunofluorescence staining with anti-cleaved-caspase-3 antibody. 40,6-Diamidino-2-phenylindole
dihydrochloride (DAPI) staining is shown in blue. Upon OSU-03012 treatment, RH30 and SMS-CTR cells showed an increased amount of caspase-3
cleavage (A). However, human fibroblast (HFF) and human skeletal muscle myoblast (HSMM) cells did not show any detectable caspase-3 cleavage after
treatment (B).
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